| 引用本文: | 江绮云,陈怡双,黄海燕,胡华钟,宋想飞,宣建伟.雷公藤多苷片联合甲氨喋呤治疗类风湿关节炎的成本效用分析[J].中国现代应用药学,2025,42(9):81-87. |
| Jiang Qiyun,CHEN Yishuang,HUANG Haiyan,HU Huazhong,SONG xiangfei,XUAN Jianwei.Cost-utility analysis of tripterygium glycosides tablets plus methotrexate in patients with rheumatoid arthritis[J].Chin J Mod Appl Pharm(中国现代应用药学),2025,42(9):81-87. |
|
| 摘要: |
| 目的 探讨雷公藤多苷片联合甲氨喋呤对比三联疗法(甲氨喋呤+柳氮磺吡啶+羟氯喹)治疗甲氨喋呤反应不足的中重度类风湿关节炎患者的成本效益。方法 从中国卫生系统的角度出发,构建微观模拟Markov模型,模型的周期为6个月,模拟的时间范围为终生,主要结局指标为总成本、质量调整生命年(QALY)。采用成本效用分析法进行分析,并采用单因素和概率敏感性分析评估模型结论的可靠性。结果 基础分析结果显示,对比三联疗法,雷公藤多苷片联合甲氨喋呤可节约成本6438.17元,增加0.18 QALYs,为绝对优势方案。单因素与概率性敏感性分析显示结果稳健。结论 综上所述,从中国卫生系统角度出发,比对三联疗法,雷公藤多苷片联合甲氨蝶呤治疗甲氨喋呤反应不足的中重度类风湿关节炎具有经济性。 |
| 关键词: 雷公藤多苷片 甲氨喋呤 三联疗法 类风湿关节炎 成本效用分析 |
| DOI： |
| 分类号:R956?????? |
| 基金项目: |
|
| Cost-utility analysis of tripterygium glycosides tablets plus methotrexate in patients with rheumatoid arthritis |
|
Jiang Qiyun,CHEN Yishuang,HUANG Haiyan,HU Huazhong,SONG xiangfei,XUAN Jianwei
|
|
The Third Affiliated Hospital, Southern Medical University
|
| Abstract: |
| OBJECTIVE To estimate the cost-effectiveness of tripterygium glycosides tablets plus methotrexate compared to triple therapy in patients with rheumatoid arthritis for whom inadequately responing to methotrexate. METHODS A microsimulation Markov model was applied from the Chinese health-care system perspective. The model cycle was 6 months, the simulated time range is lifetime, and the main outcome were total cost and quality-adjusted life years (QALY). The analysis was conducted by cost-utility analysis. To ensure the robustness of the model, one-way and probabilistic sensitivity analyses were performed to evaluate the model uncertainty. RESULTS The base-case analysis demonstrated that compared with the triple therapy, tripterygium glycosides tablets plus methotrexate was dominated, resulting in a cost-saving of ￥6438.17 and incremental QALYs of 0.18. One-way and probabilistic sensitivity analyses showed that the results to be robust. CONCLUSION Based on the above results, from the Chinese health-care system perspective, tripterygium glycosides tablets plus methotrexate is cost-effective compared to triple therapy in patients with rheumatoid arthritisfor whom inadequately responing to methotrexate. |
| Key words: tripterygium glycosides tablets methotrexate triple therapy rheumatoid arthritis cost-utility analysis |
